Skip to main content

Table 1 Changes in UUI episodes per week by dose adjustment in the TC-treatment group and the OXY- treatment group (FAS)

From: Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence

 

Trospium chloride

Oxybutynin

Time point

No Dose Adjustment

Dose Adjustment

Difference between subgroups

No Dose Adjustment

Dose Adjustment

Difference between subgroups

Entrance visit (baseline)

     

   N

546

240

 

575

192

 

   Mean ± SD

20.1 ± 17.6

22.2 ± 19.58

 

18.6 ± 16.37

20.8 ± 18.41

 

   Median

14.0

15.0

 

14.0

13.0

 

   Range

0.0 - 107.0

4.0 - 99.0

 

0.0 - 120.0

0.0 - 90.0

 

Intermediate visit

      

   N

531

241

 

561

193

 

   Mean ± SD

7.9 ± 11.97

12.2 ± 16.4

 

6.5 ± 10.32

13.4 ± 17.68

 

   Median

3.0

6.0

 

3.0

6.0

 

   Range

0.0 - 67.0

0.0 - 112.0

 

0.0 - 109.0

0.0 - 83.0

 

Final visit

      

   N

502

226

 

534

181

 

   Mean ± SD

5.4 ± 10.42

7.8 ± 12.49

 

4.4 ± 9.28

6.9 ± 13.42

 

   Median

1.0

3.0

 

0.0

1.0

 

   Range

0.0 - 64.0

0.0 - 65.0

 

0.0 - 80.0

0.0 - 100.0

 

Change from baseline to final visit

     

   N

508

228

 

537

182

 

   Mean ± SD

-14.96 ± 15.063

-14.40 ± 16.346

 

-14.29 ± 15.673

-13.56 ± 15.982

 

   Median

-11.00

-10.58

 

-10.00

-9.00

 

   Range

-107.0 - 28.0

-96.0 - 22.0

 

-105.0 - 63.0

-88.0 - 50.0

 

   Hodges-Lehmann estimate

  

-1.00

  

-1.00

   95% CI (non-parametric)

  

[-2.00; 0.00]

  

[-2.00; 1.00]

   P-value

  

0.248989

  

0.349402

  1. Note: P-values are obtained from the generalised Wilcoxon Rank sum test without stratification for centre.